Substances regulated under narcotics and psychotropics legislation due to their potential for addiction and abuse, requiring specific licensing, security, and record-keeping for manufacture, distribution, and use.
Foresight tracks Controlled Substances developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Not ready for a trial? Take the 3-minute readiness assessment
Current activity
In line with the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
24 May 2026, 21:39
Source-backed regulatory and guidance signals tracked by Foresight, with the newest developments first.
New Hampshire House Non-Concurs With Senate Amendment to HB 1423 on Synthetic Kratom Ban
New Hampshire HB 1423, which would classify synthetic and semisynthetic kratom as Schedule II controlled drugs and ban their preparation, distribution, sale, possession, and advertising outside scientific research, has hit a procedural hurdle after the House voted to non-concur with the Senate-amended version in May 2026. For kratom manufacturers, distributors, and retailers this signals a live but uncertain state-level restriction that could abruptly close the New Hampshire market for synthetic and semisynthetic kratom products if a compromise text is agreed and enacted, warranting close monitoring of further legislative moves.
United StatesUS FDA Issues Draft Guidance on Benefit-Risk Assessment for Opioid Analgesic Drugs
In May 2026, the US FDA issued draft guidance detailing how it assesses the benefit–risk balance of opioid analgesic drugs when deciding whether to approve new drug applications. This framework will shape evidence expectations and submission strategies for opioid analgesic sponsors, effectively raising the bar for how benefits and serious risks are justified in regulatory filings.
United StatesUS DEA Temporarily Schedules 2-Fluorodeschloroketamine (2-FDCK) in Schedule I
DEA has issued a temporary scheduling order placing 2-fluorodeschloroketamine (2-FDCK) and its salts and isomers in Schedule I under the US Controlled Substances Act, effective on Federal Register publication and running through 22 May 2028. This immediately moves 2-FDCK under full US controlled-substance requirements, forcing manufacturers, distributors and researchers to secure Schedule I registration, update compliance controls, or exit this market while DEA decides on permanent scheduling.
United StatesEuropean Parliament Draft Report on EU Drug Precursors Monitoring and Control Regulation
European Parliament committees have issued a joint draft report setting Parliament’s first-reading position on the proposed EU regulation to tighten monitoring and control of drug precursors, extending obligations to non-scheduled substances, online marketplaces, and high-risk category 2 precursors. This non-binding step signals likely future requirements for chemical and pharmaceutical supply chains around enhanced traceability, electronic reporting, and coordinated enforcement against emerging precursor threats.
European UnionNew Hampshire HB 1772 Would Permit Ibogaine Use Only in FDA-Approved Research
New Hampshire’s HB 1772-FN-A, now in House–Senate conference, would authorise licensed clinicians to administer ibogaine only within FDA-approved research protocols while also adopting the Physician Associate Licensure Compact. If enacted, this would open a narrow research-only pathway for ibogaine studies in New Hampshire, so healthcare providers and research sponsors should track the bill’s progress and prepare compliance, oversight and supply arrangements aligned with federal and state controls.
United StatesLouisiana SB510 Sent to Governor to Prohibit Enticing Minors Onto Premises Selling Consumable Hemp Products
Louisiana has enrolled SB510 and sent it to the Governor; the bill would extend existing minors-on-premises alcohol rules to licensed venues where consumable hemp products are the principal commodities, with a stated effective date of 1 August 2026 if enacted. Businesses in Louisiana that sell consumable hemp products alongside alcohol should anticipate stricter age-access controls on their premises and review permits, layouts, and staff procedures in light of this likely change.
United StatesUkraine Updates Unified State Register of Operators of Controlled Substances (Annex as of 19 May 2026)
Ukraine’s Ministry of Economy has issued an updated annex to the Unified State Register of Operators of Controlled Substances, reflecting the officially recognised list of authorised operators as of 19 May 2026. Companies handling ozone-depleting substances or fluorinated greenhouse gases in Ukraine should confirm their registration status in the new annex and ensure continued compliance with associated licensing, reporting, and labelling requirements.
UkraineFrance Ripost Bill Would Criminalise Non-Medical Nitrous Oxide Use and Restrict Sales to Professionals
France’s Ripost bill, now under accelerated debate in the Senate, would sharply tighten nitrous oxide controls by criminalising non-medical use, limiting sale and transport largely to authorised professionals, and adding new enforcement tools for shops, online platforms and drivers. If adopted, this would effectively treat nitrous oxide as a controlled substance in France, raising compliance and enforcement risk for manufacturers, distributors, retailers and e-commerce platforms that supply or facilitate access to the gas.
FranceDEA Final Rule Authorizes Supervisory Diversion and Intelligence Officials to Sign Administrative Subpoenas
DOJ has issued a final rule authorizing DEA Supervisory Diversion Investigators, Field Intelligence Managers, and Intelligence Group Supervisors to sign and issue administrative subpoenas under the Controlled Substances Act, effective upon Federal Register publication in May 2026. This internal delegation increases DEA’s operational capacity to compel records from registrants and precursor handlers, modestly heightening enforcement reach and investigative touchpoints for companies in controlled-substance supply chains.
United StatesUS DEA Comment Period on Amneal Pharmaceuticals Remifentanil Importer Registration Application
The US Drug Enforcement Administration has opened a Federal Register comment period on Amneal Pharmaceuticals’ application to import the Schedule II opioid remifentanil, with objections and hearing requests due by 22 June 2026. This signals a potential expansion of remifentanil supply under existing US controlled substances law without changing its scheduling, so only manufacturers and applicants active in this class are likely to need to consider commenting or monitoring the outcome.
United StatesCalifornia Senate Passes SB 1306 Exempting Certain Gamma-Butyrolactone Mixtures From Controlled Substances Reporting
In May 2026 the California Senate passed SB 1306, a bill that would add Section 11112 to the Health and Safety Code to exempt certain low-concentration gamma-butyrolactone (GBL) mixtures from state precursor-chemical permitting and reporting rules. If enacted, the measure would ease compliance for chemical suppliers and semiconductor manufacturers handling GBL-based mixtures by aligning California more closely with federal DEA exemptions while keeping pure GBL tightly controlled.
United StatesUS DEA Updates Exempt Chemical Preparations Under the Controlled Substances Act
The US Drug Enforcement Administration has issued an order updating which analytical standards and calibrator solutions qualify as exempt chemical preparations under the Controlled Substances Act, approving some applications and denying others following submissions through 31 March 2026. Manufacturers and laboratories handling controlled-substance reference materials should verify whether their specific products now fall on the exempt or non-exempt lists and prepare comments or compliance adjustments ahead of the 60-day comment deadline.
United StatesUS DEA Announces Bulk Manufacturer Registration Application for Methamphetamine by Organix Chemistry Solutions LLC
On 20 May 2026 the US Drug Enforcement Administration published a notice that Organix Chemistry Solutions LLC has applied to register as a bulk manufacturer of the Schedule II controlled substance methamphetamine, with comments and hearing requests due by 20 July 2026. If approved, this registration would create a new licensed source of a tightly controlled active ingredient, so existing manufacturers and supply-chain stakeholders may wish to review the application and consider commenting or adjusting their planning.
United StatesEU Council Working Party on Customs Union To Discuss Drug Precursors Proposal and HS Modernisation on 21 May 2026
The Council of the EU has published the 21 May 2026 agenda for its Customs Union Working Party, confirming discussions on HS modernisation and the recast regulation on monitoring and controlling drug precursors. These meetings signal ongoing Council-level work that could tighten controls on drug precursors and reshape customs classifications, so affected businesses should track the legislative progress and anticipate future compliance changes.
European UnionUS DEA Proposes Revisions to Quota Applications for Controlled Substances and List I Chemicals
The US Drug Enforcement Administration has proposed revising its manufacturing and procurement quota regulations for schedule I and II controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, with public comments due by 20 July 2026. If adopted, the rule will require manufacturers to provide detailed production-cycle data and distinguish domestic versus export quotas, giving DEA greater visibility into controlled substance supply chains and potential shortages while increasing data and planning demands on quota applicants.
United StatesCalifornia AB 2537 Ordered to Third Reading — Cannabis Enforcement Accountability and Public Health Prioritization Act
California’s AB 2537 Cannabis Enforcement Accountability and Public Health Prioritization Act has advanced to third reading in the Assembly, proposing a risk-based framework for enforcing the state’s cannabis regime. If enacted, it would push the Department of Cannabis Control to focus enforcement and public reporting on unlicensed operators, synthetic cannabinoids, unsafe or misbranded products, and weak testing, recordkeeping and workplace practices, heightening compliance scrutiny for cannabis businesses and laboratories.
United StatesUS DEA Seeks Comment On Benuvia Application To Bulk Manufacture Schedule I and II Controlled Substances
In May 2026, the US Drug Enforcement Administration published a Federal Register notice on Benuvia Operations, LLC’s application to register as a bulk manufacturer of multiple Schedule I and II controlled substances, with a 60-day comment and hearing-request period. If granted, this licence would expand US manufacturing capacity for psychedelics and other tightly controlled active ingredients, so affected manufacturers and applicants should review potential competitive and supply-chain implications before the 17 July 2026 deadline.
United StatesNew Jersey Assembly Passes A5051 on Hemp, Intoxicating Hemp Beverages, and Medical Cannabis
In May 2026, the New Jersey Assembly passed Bill A5051 to tighten controls on hemp-derived cannabinoids, intoxicating hemp beverages, and aspects of medical cannabis licensing, and sent it to the Senate Judiciary Committee. If enacted, the measure would impose stricter THC content and packaging standards, extend temporary allowances to November 2026, and lock in new permissions for some dispensaries, forcing beverage, cannabis, and retail operators in New Jersey to reassess products, distribution, and compliance timelines.
United StatesUS FDA Warns FATZorb Weight-Loss Product Contains Hidden Prescription Drug Ingredients
The US FDA has warned that the FATZorb weight-loss product contains undisclosed prescription drug analogues of sibutramine and the laxative phenolphthalein, and has advised consumers not to purchase or use it due to serious cardiovascular and cancer-risk concerns. This underscores persistent safety and compliance risks from adulterated “all natural” weight-loss supplements sold online and in retail, pressuring manufacturers, distributors, and platforms to strengthen supplier controls, surveillance, and response to similar hidden-ingredient products.
United StatesMinnesota Legislature Approves Pharmacist Authority To Prescribe Schedule III–V Drugs for Opioid Use Disorder
Minnesota lawmakers have advanced omnibus bill H.F. 4074 adding a new statutory subdivision that would allow trained pharmacists to prescribe, administer, and dispense certain Schedule III–V medications to treat opioid use disorder. If enacted, this will expand access to OUD treatment through pharmacies but will require additional training, DEA registrations, documentation, and protocols to manage controlled-substance and clinical governance risk.
United StatesThese are just a few of the most recent Controlled Substances alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Start free trialTopic context
Definition
Substances regulated under narcotics and psychotropics legislation due to their potential for addiction and abuse, requiring specific licensing, security, and record-keeping for manufacture, distribution, and use.
Industry relevance
Controlled Substances developments can change product scope, supplier expectations, market access, reporting duties, and risk ownership. Foresight tracks the signals early so teams can respond before obligations become urgent.
Foresight tracking
Foresight monitors official sources, extracts structured regulatory intelligence, and maps alerts to a customer's products, substances, markets, and priorities so teams see the relevant signal with source evidence for review.
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
